Navigation Links
Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
Date:5/24/2010

oing trials of our ZFN-based technology.  At the same time, with our collaborators, we continue to define and develop new therapeutic opportunities."

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic™ development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFN) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at http://www.sangamo.com/.

This press release may contain forward-looking statements based on Sangamo's current
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
2. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
3. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
4. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
5. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
6. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
7. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
8. Sangamo Announces Pricing of Public Offering of Common Stock
9. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
10. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
11. Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... YORK , Oct. 22, 2014 Nuvilex, ... Federation, approximately 400 million people worldwide are living with ... million people by 2030.  The global market for diabetes ... 2012 approximately 330,000 people worldwide died from pancreatic cancer.  ... death due to cancer in the United ...
(Date:10/20/2014)... Mapp Biopharmaceutical,s valiant effort to produce ... fight the Ebola outbreak will make the public ... of pharmaceuticals can be, according to Kalorama Information.  ... some may be taken aback by the three-month ... knowledge are well aware of the complex issues ...
(Date:10/20/2014)... -- , A major pan-European survey into ... of care has revealed changing trends in many important ... provision of healthcare services across the continent. The results ... Gastroenterology (UEG), have been announced today and led to ... burden of GI disorders across Europe ...
(Date:10/20/2014)... October 20, 2014 Earle ... LLC, announced today that Ellen Teplitzky, an experienced ... for the pharmaceutical industry, has joined the firm ... its legal services practice. NDA Partners provides ... witness and testimony, to top law firms and ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... Standards and Technology (NIST) colored lots of eggs recently. ... smallin fact, too small to see without a microscope. ... strategies for making future low-power computer memories. For ... used electron-beam lithography to make thousands of nickel-iron magnets, ...
... new kind of cloaking material that can render ... this design can,t translate into an invisibility cloak ... in diagnostics, security, and communication. The cloak, ... engineering at Northwestern,s McCormick School of Engineering and ...
... 27, 2011 Talecris Biotherapeutics Holdings Corp. ("Talecris") (NASDAQ: ... for the three months ended March 31, 2011 and ... Exchange Commission (SEC). First quarter 2011 net ... million from $381.0 million in the first quarter of ...
Cached Biology Technology:Good eggs: NIST nanomagnets offer food for thought about computer memories 2Researchers create terahertz invisibility cloak 2Talecris Biotherapeutics Announces First Quarter 2011 Results 2Talecris Biotherapeutics Announces First Quarter 2011 Results 3Talecris Biotherapeutics Announces First Quarter 2011 Results 4Talecris Biotherapeutics Announces First Quarter 2011 Results 5Talecris Biotherapeutics Announces First Quarter 2011 Results 6Talecris Biotherapeutics Announces First Quarter 2011 Results 7Talecris Biotherapeutics Announces First Quarter 2011 Results 8Talecris Biotherapeutics Announces First Quarter 2011 Results 9Talecris Biotherapeutics Announces First Quarter 2011 Results 10Talecris Biotherapeutics Announces First Quarter 2011 Results 11Talecris Biotherapeutics Announces First Quarter 2011 Results 12Talecris Biotherapeutics Announces First Quarter 2011 Results 13Talecris Biotherapeutics Announces First Quarter 2011 Results 14Talecris Biotherapeutics Announces First Quarter 2011 Results 15Talecris Biotherapeutics Announces First Quarter 2011 Results 16
(Date:10/19/2014)... electricity access in India over the last 30 ... carbon emissions growth during that time, according to ... Nature Climate Change ., "Energy access is fundamental ... of life, including education, communication, and health," says ... , While increased energy access is widely agreed ...
(Date:10/18/2014)... a group of 2,000 patients referred for evaluation ... potential molecular diagnosis for 25 percent, including detection ... new mutations contributing to disease, according to a ... is being released to coincide with the American ... sequencing analyzes the exons or coding regions of ...
(Date:10/17/2014)... – Accurate knowledge regarding Ebola is critical and pertinent ... of hazardous global outbreak and epidemic. The Journal, ... a special issue, Ebola Virus and Public Health, to ... knowledge in this critical societal moment. , On ... Ebola for Clinicians . The primer was prepared by ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Whole-exome sequencing shows potential as diagnostic tool 2
... 28, 2011) University of Kentucky plant pathologists recently discovered ... the ability of plants, animals, humans and one-celled microorganisms to ... level, which is known as systemic immunity. This mode of ... the key events that stimulate that resistance have remained a ...
... Western Reserve University has detected tiny amounts of Iodine 131 ... campus building. Gerald Matisoff, professor of geology, said ... health. He estimated the level of radiation is about one-tenth ... 131 could have come from any radioactive waste processing facility," ...
... of scientists has discovered that descendants of "exploratory" butterflies ... cautious cousins. The team, led by James Marden, a ... Wheat, a post-doctoral scholar working at both Penn State ... the genetic bases for faster egg maturation, a higher ...
Cached Biology News:Kentucky researchers find a key to plant disease resistance 2Butterfly study reveals traits and genes associated with establishment of new populations 2Butterfly study reveals traits and genes associated with establishment of new populations 3Butterfly study reveals traits and genes associated with establishment of new populations 4
...
... High pH This pH 9.9 solution ... to immunohistochemical staining procedures. It is for ... on glass slides. For particular antigens, target ... effective. It should be noted that also ...
... A very potent Rnase ... effective over a broad range ... This protein does not inhibit ... polymerase, AMV and M-MLV reverse ...
... Dako Target Retrieval Solution, pH 9 (x ... buffer, pH 9, intended for heat-induced target ... is well-suited for use on formalin-fixed, paraffin-embedded ... with 0.01 mol/L citrate buffer, pH 6, ...
Biology Products: